{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-078622","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.569459+00:00","generated_at":"2026-06-01T01:08:16.802852+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting","bullets":["Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.","Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.","Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.","Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-078622","json":"https://secwatch.observer/filing/0000950170-24-078622.json","markdown":"https://secwatch.observer/filing/0000950170-24-078622.md","text":"https://secwatch.observer/filing/0000950170-24-078622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/0000950170-24-078622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/sabs-20240627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:08:16.802852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}